Moltó, J., Santos, J. R., Pérez-Álvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. American Society for Microbiology (ASM).
Chicago-tyylinen lähdeviittausMoltó, José, et al. Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. American Society for Microbiology (ASM), 2008.
MLA-viiteMoltó, José, et al. Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. American Society for Microbiology (ASM), 2008.